Verastem, Inc.
NASDAQ:VSTM
Overview | Financials
Company Name | Verastem, Inc. |
Symbol | VSTM |
Currency | USD |
Price | 5.04 |
Market Cap | 224,312,760 |
Dividend Yield | 0% |
52-week-range | 2.1 - 14.22 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel W. Paterson |
Website | https://www.verastem.com |
An error occurred while fetching data.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD